HK1223101A1 - -異丙基- -甲基- -三唑- -基 -二氫苯並 咪唑並 氧氮雜䓬- -基 -吡唑- -基 -甲基丙酰胺的多晶型物、其製備方法和藥物用途 - Google Patents
-異丙基- -甲基- -三唑- -基 -二氫苯並 咪唑並 氧氮雜䓬- -基 -吡唑- -基 -甲基丙酰胺的多晶型物、其製備方法和藥物用途Info
- Publication number
- HK1223101A1 HK1223101A1 HK16111381.6A HK16111381A HK1223101A1 HK 1223101 A1 HK1223101 A1 HK 1223101A1 HK 16111381 A HK16111381 A HK 16111381A HK 1223101 A1 HK1223101 A1 HK 1223101A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- oxazepin
- methylpropanamide
- dihydrobenzo
- polymorphs
- imidazo
- Prior art date
Links
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916657P | 2013-12-16 | 2013-12-16 | |
| PCT/EP2014/077666 WO2015091305A1 (en) | 2013-12-16 | 2014-12-15 | Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1223101A1 true HK1223101A1 (zh) | 2017-07-21 |
Family
ID=52023532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16111381.6A HK1223101A1 (zh) | 2013-12-16 | 2016-09-29 | -異丙基- -甲基- -三唑- -基 -二氫苯並 咪唑並 氧氮雜䓬- -基 -吡唑- -基 -甲基丙酰胺的多晶型物、其製備方法和藥物用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9266903B2 (zh) |
| EP (1) | EP3083640A1 (zh) |
| JP (2) | JP6302089B2 (zh) |
| KR (2) | KR20180093138A (zh) |
| CN (2) | CN105829323B (zh) |
| AR (1) | AR098762A1 (zh) |
| AU (3) | AU2014365079B2 (zh) |
| BR (1) | BR112016009665A8 (zh) |
| CA (1) | CA2927125A1 (zh) |
| HK (1) | HK1223101A1 (zh) |
| IL (2) | IL244915A0 (zh) |
| MX (1) | MX356804B (zh) |
| RU (2) | RU2018119749A (zh) |
| SG (3) | SG10201705673QA (zh) |
| TW (2) | TW201731852A (zh) |
| WO (1) | WO2015091305A1 (zh) |
| ZA (1) | ZA201602534B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2981159A1 (en) * | 2015-06-29 | 2017-01-05 | F. Hoffmann-La Roche Ag | Methods of treatment with taselisib |
| EP4272735A1 (en) * | 2015-06-30 | 2023-11-08 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| MX2019012507A (es) | 2017-04-28 | 2019-12-19 | Hoffmann La Roche | Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil) -2-oxooxazolidin-3-il)-5,6-dhidrobenzo[f]midazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion. |
| KR20200091395A (ko) * | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5540101B2 (ja) | 2009-09-28 | 2014-07-02 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンｐｉ３ｋ阻害剤化合物及び使用方法 |
| CN104379163A (zh) * | 2012-06-08 | 2015-02-25 | 霍夫曼-拉罗奇有限公司 | 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合 |
| NZ711192A (en) * | 2013-03-13 | 2019-04-26 | Hoffmann La Roche | Process for making benzoxazepin compounds |
-
2014
- 2014-12-15 WO PCT/EP2014/077666 patent/WO2015091305A1/en active Application Filing
- 2014-12-15 RU RU2018119749A patent/RU2018119749A/ru unknown
- 2014-12-15 JP JP2016558275A patent/JP6302089B2/ja active Active
- 2014-12-15 TW TW105143616A patent/TW201731852A/zh unknown
- 2014-12-15 RU RU2016127039A patent/RU2658009C2/ru not_active IP Right Cessation
- 2014-12-15 AU AU2014365079A patent/AU2014365079B2/en not_active Ceased
- 2014-12-15 SG SG10201705673QA patent/SG10201705673QA/en unknown
- 2014-12-15 US US14/570,019 patent/US9266903B2/en active Active
- 2014-12-15 CN CN201480068672.4A patent/CN105829323B/zh active Active
- 2014-12-15 EP EP14811921.7A patent/EP3083640A1/en not_active Withdrawn
- 2014-12-15 KR KR1020187023324A patent/KR20180093138A/ko not_active Application Discontinuation
- 2014-12-15 KR KR1020167015862A patent/KR101902664B1/ko active IP Right Grant
- 2014-12-15 MX MX2016007581A patent/MX356804B/es active IP Right Grant
- 2014-12-15 CA CA2927125A patent/CA2927125A1/en not_active Abandoned
- 2014-12-15 SG SG10201705669QA patent/SG10201705669QA/en unknown
- 2014-12-15 BR BR112016009665A patent/BR112016009665A8/pt not_active Application Discontinuation
- 2014-12-15 SG SG11201604903VA patent/SG11201604903VA/en unknown
- 2014-12-15 CN CN201811256901.1A patent/CN109293674A/zh active Pending
- 2014-12-15 AR ARP140104667A patent/AR098762A1/es unknown
- 2014-12-15 TW TW103143724A patent/TWI638818B/zh not_active IP Right Cessation
-
2016
- 2016-01-08 US US14/991,658 patent/US9481690B2/en active Active
- 2016-04-05 IL IL244915A patent/IL244915A0/en unknown
- 2016-04-14 ZA ZA201602534A patent/ZA201602534B/en unknown
- 2016-09-29 HK HK16111381.6A patent/HK1223101A1/zh unknown
- 2016-11-14 IL IL248965A patent/IL248965A0/en unknown
-
2017
- 2017-06-06 AU AU2017203817A patent/AU2017203817B2/en not_active Ceased
- 2017-06-06 AU AU2017203819A patent/AU2017203819B2/en not_active Ceased
- 2017-12-20 JP JP2017244553A patent/JP2018080179A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400010I1 (hu) | Bardoxolon metil 2,2-difluorpropionamid-származékai, azok polimorf formái és eljárások alkalmazásaikra | |
| EP3371187A4 (en) | 2- (1H-INDAZOLE-3-YL) -3H-IMIDAZO [4,5-C] PYRIDINE AND ITS USE AS AN INHIBITOR OF INHIBITOR | |
| EP3173412A4 (en) | 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| IL267464A (en) | Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepin-9-yl)amino)propanamide and methods of production | |
| PL2834248T3 (pl) | Nowe pochodne tienopirymidynowe, sposoby ich otrzymywania i ich zastosowania terapeutyczne | |
| EP2834224A4 (en) | PROCESSES FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | |
| EP2957666A4 (en) | Towel product, and manufacturing method for towel product | |
| HK1223101A1 (zh) | -異丙基- -甲基- -三唑- -基 -二氫苯並 咪唑並 氧氮雜䓬- -基 -吡唑- -基 -甲基丙酰胺的多晶型物、其製備方法和藥物用途 | |
| HK1225723A1 (zh) | 取代的咪唑並[1，2-a]吡啶甲酰胺及其用途 | |
| IL281087A (en) | Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide | |
| HK1201060A1 (zh) | -二甲基苯基 -丙醛的製備方法 | |
| EP3004085A4 (en) | IMIDAZOLE DERIVATIVES AND METHODS OF USE FOR ENHANCING THE PHARMACOKINETICS OF A MEDICAMENT | |
| EP3068391A4 (en) | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug | |
| EP2842940A4 (en) | SULFORAPHANE DERIVED COMPOUNDS, METHOD FOR OBTAINING SAME, AND MEDICAL, FOOD, AND COSMETIC USE THEREOF | |
| HK1212968A1 (zh) | 氨基環丁烷衍生物、其製備方法及其用作藥物的用途 | |
| ZA201407558B (en) | Itq-49 material, method for the production thereof and use of same | |
| EP2835372A4 (en) | THIOPHENE [2, 3-D] PYRIMIDINE DERIVATIVE AND METHOD OF PREPARATION AND USE | |
| AP3759A (en) | Method for preparing phenyloxymethyl-nitro-imidazole derivatives and use of the same | |
| PL2863887T3 (pl) | Emulsja do zastosowania farmaceutycznego i sposób jej wytwarzania | |
| ZA201201061B (en) | Process for the preparation of bromopyrimidine derivative | |
| PL399422A1 (pl) | Sposób wytwarzania 2',4,4',6'-tetrahydroksydihydrochalkonu | |
| PL399423A1 (pl) | Sposób wytwarzania 2'-hydroksydihydrochalkonu |